NCT00549900View on ClinicalTrials.gov

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 2, 2007

Primary Completion Date

July 12, 2008

Study Completion Date

July 12, 2008

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)

Intramuscular injection, 3 doses

Trial Locations (1)

Unknown

GSK Investigational Site, Jintan

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY